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~bstract Oligodeoxycytidylates were converted to s4dUMP - 
~ontaining oligomers by treatment with liquid H2S. The 
inhibitory potency of the modified oligonucleotides on human 
immunodeficiency virus type 1 reverse transcriptase depended on 
t he chain length and on the percentage of modification. The most 
potent reverse transcriptase inhibitor was (s4dU)35 . The inhibi- 
tory pattern was competitive, when either poly(A)'(dT)t6 or 
poly(C)'(dG)16 was used as template-primer (variable substrate), 
suggesting that the free enzyme interacts with (s4dU)35 . The Ki 
~ahies were 3.0 and 2.2 nM in the presence of poly(A)-(dT)16 and 
poly(C)'(dG)16, respectively. 
.~ey wordr." Inhibition; Reverse transcriptase; Human 
~mmunodeficiency virus; Oligo 4-thio-2'-deoxyuridylate: 
~mtitemplate 
• Introduction 
Reverse transcriptase (EC 2.7.7.49) represents one of the 
main targets in the development of the chemotherapy against 
HIV, the etiological agent of the acquired immunodeficiency 
.yndrome [1]. Therefore, a large number of nucleoside and 
non-nucleoside RT inhibitors have been studied recently as 
i~otential agents against AIDS [2-5]. 
Chemically modified oligo- and polynucleotides have also 
~een studied and characterized as inhibitory template (or 
'~rimer) analogs for DNA polymerases including RT. They 
rove been termed antitemplates [6]. The antitemplates interact 
vith proteins (i.e. template dependent nucleic acid poly- 
nerases) rather than nucleic acids (antisense ffect). Their ac- 
ivities are not strictly dependent on specific nucleic acid se- 
luences. In addition to the nucleoside and non-nucleoside 
'ype inhibitors the modified oligonucleotides are another class 
,~f RT inhibitors. 
The most thoroughly studied inhibitory template analogs 
tre 5-mercaptopyrimidine-containing polynucleotides [7-9]. 
['hey are potent inhibitors of the replication of HIV in pri- 
nary  human lymphocytes [10]. The poly(U60,hsSU40) proved 
o be a potent competitive inhibitor of RT [11]. The phos- 
~horothioate-linked and phosphorodithioate-linked oligo- 
leoxycytidylate analogs are also potent competitive inhibitors 
ff viral DNA polymerases [12-15]. A pentose modified oligo- 
mcleotide, 13-4'-thio-oligouridylate, has been shown recently 
o interact with HIV-1 RT [16]. It was shown earlier that 
poly(s4U), a base modified polyribonucleotide, inhibits the 
virion-associated transcriptase of influenza A [17]. 
In this paper we report the HIV-1 RT inhibitory activity of 
oligonucleotides containing s4dUMP. 
2. Materials and methods 
2.1. Materials 
The unlabeled eoxyribonucleotides TTP, dGTP ('Ultrapure') as 
well as poly(A) and poly(C) were Pharmacia products. The labelled 
nucleotides [aH]dTTP and [3H]dGTP were from Amersham. All other 
reagents were of the highest quality commercially available. 
HIV-1 RT was purchased from Worthington (Freehold, NJ). Its 
concentration was 8 U/gl, Lot No. 63E792N. The alkaline phospha- 
tase (grade I) and phosphodiesterase ( nake venom nuclease from 
Crotalus durissus) were purchased from Boehringer Mannheim (Ger- 
many). 
The template-primers were poly(A)'(dT)a~i and poly(C)'(dGh6, pre- 
pared as described earlier [1 I]. 
The oligodeoxycytidylates were synthesized on a Pharmacia Gene 
Assembler Plus DNA synthesizer in our laboratory and purified by 
two precipitations with n-butanol. 
2.2. Synthes& and character&ation of s4dU containing oligonucleotides, 
( dCx,s4 dUv ),~ 
The thiolated oligonucleotides were prepared by treating 1.5-3.5 mg 
of (dC)n (n = 10, 20, 25, 30, 35, 40), dissolved in aqueous pyridine, with 
liquid H2S [18,19] for 2-10 days at 35°C or 50°C, depending on the 
desired degree of thiolation. The modified oligonucleotides were iso- 
lated by ethanol precipitation as described for modified 5S rRNA [20], 
or were isolated on a DEAE Sephacell (Pharmacia) column, prepared 
in a 1 ml pipette tip (CI form, volume about 0.3 ml). A stepwise 
elution with increasing concentration of KC1 was performed to isolate 
the oligonucleotides. 
The base ratio of the modified oligonucleotides was determined by 
HPLC, after hydrolysis to nucleosides with snake venom diesterase 
and alkaline phosphatase [21]. The deoxycytidine and 4-thiodeoxyuri- 
dine contents of aliquots were analyzed on a Cls column (Nova-Pak, 
3.9 × 150 mm) using a 15-ml linear gradient of 0-10% acetonitrile in 
0.1 M sodium phosphate (pH 5.8) at a flow rate of 1.0 ml/min. Only 
two peaks were detected. The chromatography was monitored at 254 
nm. The following elution times were observed: 5 min for dC, 12.1 
min for s'ldU. The areas under each peak were determined by inte- 
gration and the amounts of each nucleoside present were determined 
using the following extinction coefficients (M- ~ cm-1): dC(6.2 × 103), 
sndu(Y3 × 103). The composition of the oligonucleotides according to 
the HPLC analysis were in accordance with their observed UV spec- 
tra. In order to determine the exact concentration of the modified 
oligonucleotides their organic phosphate contents were measured [22]. 
The following oligonucleotides were prepared and used in this 
study: (dC)35, (s4dU)10, (s~dU)20, (s4dU)25, (s4dU)30, (s4dU)35, 
(s~dU)m, (dCii.5o,s4dUoso)35, (dC05s,s4dU042)35, (dCo.66,s~dUo.3,1)35, 
(dCt~.73,s tdU0.27)35. 
~Corresponding author. Fax: (36) (52) 416-432. 
lbbreviations: RT, reverse transcriptase; HIV, human immunodefi- 
ciency virus; AIDS, acquired immunodeficiency s ndrome; TCA, 
~richloroacetic a id; Na-PPi, Na-pyrophosphate 
2.3. R T assays 
Reaction mixtures were incubated for 45 min at 37°C. In a final 
volume of 100 lal they contained the following: 100 mM Tris-HC1 (pH 
8.0), 50 mM KC1, 6 mM MgC12, 100 gg/ml bovine serum albumin, 5 
mM dithiothreitol, 10 gM [3H]dTTP or [3H]dGTP (specific activity 
4400 dpm/pmol), and 0.1 gM template-primer ( xpressed as 3'-primer 
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termini) and 0.008 U of enzyme. To study the inhibitory activity of 
the thiolated oligonucleotides theconcentration f the template-prim- 
er was changed as indicated in the legends of the figures. The reac- 
tions were terminated by the addition of 10% cold TCA containing 
100 mM Na-PPi. The radioactive product was collected by filtration 
on Whatman GF/C filter, washed four times with 1 ml of 5% TCA 
containing 50 mM Na-PPi and finally with ethanol. Filter disks were 
dried and nucleotide incorporation was quantified by scintillation 
counting. 
2.4. Kinetic analysis 
Kinetic results were evaluated graphically by plotting 1/V against 
inhibitor concentration (Dixon equation). The data points shown for 
the determination f kinetic onstants are the average from triplicate 
determinations. All lines were obtained from unweighted least squares 
fit to the data points. 
3. Results and discussion 
In preliminary experiments it was shown in our laboratory 
that oligonucleotides containing s4dU inhibit HIV-I RT. 
First we studied the effect of the chain length on the RT 
inhibitory activity of (s4dU)n (n = 10, 20, 25, 30, 35, 40). A 
dramatic increase in the inhibitory activity was observed with 
increasing chain length of the modified nucleotide (Fig. 1). 
While the 10-mer showed very little inhibitory activity the 
25~0-mers were potent inhibitors of HIV-1 RT, with practi- 
cally the same IC50 values (results for the 40-mer are not 
shown). Further increase in the chain length did not signifi- 
cantly affect the inhibitory activities of the modified oligonu- 
cleotides. The size dependence of the inhibitory potential of 
the modified polynucleotides is in good agreement with the 
structure and mechanism of HIV-1 RT. While data, based on 
3.5 A resolution electron density map of HIV-1 RT, demon- 
strate that the number of nucleotides between the polymeriza- 
tion site and RNA cutting site is 20 [23], enzymatic footprint- 
ing suggests that an even larger portion of the template- 
primer is encompassed by the replicating enzyme [24]. 
In this experiment the template-primer was poly(A)'(dT)16. 
Interaction between the template-primer and the inhibitor 
(which is an oligouridylate analog) cannot be ruled out com- 
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Fig. l. Effect of (s4dU)n on HIV-1 reverse transcriptase. The assays 
were carried out as described in Section 2; template-primer: 
poly(A)'(dT)16, n= 10 (O), 20 (,7), 25 (v ) ,  30 (O), 35 (B). 
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Fig. 2. Effect of (dCx,s4dUy)35 on HIV-I reverse transcriptase. The 
assays were carried out as described in Section 2; template-primer: 
poly(A)'(dT)16, x = 1.00 y = 0.00 (z~), x = 0.73 y = 0.27 (ll), x = 0.66 
y=0.34 ([Z), x=0.57 y=0.43 (v), x=0.50 y=0.50 (v), x=0 
y :  l.OO (e). 
pletely. However, the significant differences found in the in- 
hibitory potential of the 10-mer, 20-mer and 25-mer suggest 
an interaction between RT and the inhibitor. 
The degree of chemical modification was one of the impor- 
tant factors affecting the inhibitory potential of the s4dUMP 
containing oligonucleotides. A series of 35-mers was prepared 
by shorter or milder H2S treatment of (dC)35 as described in 
Section 2. It is evident from the results in Fig. 2 that the 
inhibitory activity of the oligonucleotides depends on the de- 
gree of modification. The inhibitory potential was increased 
when the modified nucleotide content was higher. Due to the 
nature of the chemical modification the distribution of the 
thiolated bases within the oligonucleotide must be random 
as was found in the case of partially 5-thiolated poly(C) [7]. 
These results indicated that the oligonucleotides composed 
exclusively of s4dU, with a chain length of at least 30, are the 
most potent inhibitors of this type on HIV-1 RT. 
The sulfur-containing oligo- and polynucleotides studied 
thus far have proved to be competitive inhibitors of the RT 
with respect o the functioning template-primers [11-13,15]. 
(s4dU)35 was expected to be a new member of this family of 
inhibitors. Therefore the template-primers poly(A)'(dT)16 and 
poly(C)'(dG)16 were chosen as variable substrates in the 
Dixon plot experiments shown in Figs. 3 and 4. The results 
clearly indicated that (s4dU)35 was a competitive inhibitor of 
RT with respect o the template-primers. The graphically de- 
termined Ki values were essentially the same: 3.0 nM for the 
poly(A)'(dT)16-directed reaction and 2.2 nM for the poly- 
(C).(dG)x6-directed reaction, verifying our earlier conclusion 
that the inhibitory activity of the modified oligonucleotide 
was due to a protein-oligonucleotide int raction and the tem- 
plate-primer function was not affected by (s4dU)a.~. 
It must be noted that a chemical modification is usually not 
complete. Although the HPLC analysis of our 'fully modified' 
oligonucleotides could not detect any tinmodified cytidine a 
minute amount of unmodified base may be present in the 
inhibitory oligonucleotide, not significantly affecting its in- 
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hibitory potential. A difference between the chemically pro- 
duced and enzymatically synthesized poly(s4U) was found 
~xhen the modified polynucleotides were used in protein 
synthesizing systems [25,26]. While the chemically produced 
Foly(s4U) could not direct the synthesis of polyphenylalanine 
in an in vitro protein synthesizing system [25], the enzymati- 
c dly produced polymer served as an artificial mRNA [26]. It 
s lould be pointed out that the two systems, protein synthesis 
a ad inhibition of nucleic acid synthesis, cannot be compared. 
*I he protein synthesis is strictly dependent on the sequence of 
I ~e mRNA. A minute amount of unmodified nucleotide (in 
~is  case cytidylate) can stop the in vitro incorporation of 
I henylalanine (for example CUU is a code for Leu), but the 
i lhibitory potential of an oligonucleotide is barely affected by 
very low amount of unmodified base. 
The chemically modified oligonucleotides with potent inhib- 
i ory potential on HIV RT are physico-chemically distinct 
tompounds, with the same inhibitory patterns [11,13,15]. 
"hey are competitive inhibitors. In accordance with the anti- 
: ~mplate mode of action [6], it can be presumed that the in- 
i ibitory oligonucleotide (which must be a 30-mer for full ac- 
vity) interacts with a large number of physico-chemically 
, istinct side chains of amino acids of the RT. This multi- 
ite and multi-mode interaction may explain why the inhibi- 
a ry  patterns are the same on RT for physico-chemically dis- 
tnct modified oligonucleotides [11]. The dependence of the 
lhibitory activity on the chain length found in the present 
• tudy verifies the multi-site interaction. 
The hydrophobic haracter of (s4dU)35 (see the retention 
ime for 4-thiouridine compared to cytidine in Section 2) 
rest be one of the reasons for its increased affinity for the 
nzyme, as it was presumed in the case of the phosphorothio- 
te and phosphorodithionate oligonucleotides [12,15]. The 
-thiono group has a propensity toward tautomeric onver- 
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~ig. 3. Dixon plot for inhibition of HIV-I reverse transcriptase by 
s4dU)a5 using poly(A)'(dT)16 as template-primer and variable sub- 
~;trate. Substrate concentrations (expressed as 3'-primer termini of 
~emplate-primers): 45 nM (O), 60 nM (v), 75 nM (v), 90 nM (D). 
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Fig. 4. Dixon plot for inhibition of HIV-1 reverse transcriptase by 
(s4dU)a5 using poly(C).(dG)l~ as template-primer and variable sub- 
strate. Substrate concentrations (expressed as 3'-primer termini of 
template-primers): 45 nM (O), 60 nM (v), 75 nM (v), 90 nM (1:5). 
sion to form the -SH group at position 4, The 4-SH group 
may interact with mercapto-groups of the protein to form 
temporary disulfide bridges. Both of these interactions might 
contribute to the inhibitory activity of (s4dU):~5. 
RT catalyzes DNA synthesis in an ordered sequential man- 
ner. First, the template-primer binds to the free enzyme. The 
deoxynucleoside triphosphate to be incorporated then binds 
to the binary complex. This relatively simple mechanism was 
specified recently [27,28], suggesting a two-step process in 
both cases. After initial binding of the template, the confor- 
mation of the enzyme changes and a more stable complex is 
formed. The antitemplates, being close structural analogs of 
the natural templates, may induce the conformation change of 
RT similarly to the functional counterparts. 
The (s4dU)35 was a potent inhibitor of the enzyme, thus 
being a new member of the antitemplate inhibitors of HIV-1 
RT. The antitemplate mode of action involves a multi-site and 
multi-mode interaction between the enzyme and modified oli- 
gonucleotides. The development of resistance to such a com- 
plex multi-site interacting drug is not very likely. We believe 
that the further evaluation of the antitemplates (including 
s4dU-containing oligonucleotides) as potential agents for the 
treatment of HIV infection is warranted. 
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